CDC and FDA Investigate a Multistate Cluster of Illnesses Tied to Compounded Injectable Glutathione

Federal health officials have opened a coordinated look at a product sold widely through wellness and telehealth channels. As of September 15, 2026, the U.S. Centers for Disease Control and Prevention (CDC) says it is working with the U.S. Food and Drug Administration (FDA), state and local health departments, and state boards of pharmacy to investigate illnesses in people who received injectable glutathione that compounding pharmacies prepared using an ingredient labeled for dietary supplement use rather than for injection.

The agencies describe reported adverse events, not confirmed infections spreading between people. The suspected hazard is bacterial endotoxin carried by an ingredient that was never intended to be injected. This piece summarizes what the CDC and FDA have published, what remains unverified, and why the compounded injectable market that reaches patients through telehealth is central to the concern.

What the CDC and FDA are investigating

According to the CDC's current-situation summary, the agency and its partners are investigating reports of illness in people who received injectable glutathione. The products at issue were compounded by pharmacies using glutathione ingredients intended for dietary supplements. The CDC frames this as an active investigation coordinated with the FDA, state and local health departments, and state boards of pharmacy, which means the case count and other details can change as more reports are reviewed.

Glutathione is a naturally occurring tripeptide often marketed through wellness clinics for energy, antioxidant support, skin lightening, and so-called detox. Injectable glutathione sold in these settings is a compounded preparation, not an FDA-approved drug product, so its quality depends on the compounding pharmacy and the ingredients it uses.

How many people are affected, and where

As of September 15, 2026, the CDC reports the following in its published summary:

• More than 25 people have become ill.
• Cases span at least four states: Texas, Washington, Florida, and New York.
• At least three patients have been hospitalized.
• No deaths have been reported.

The FDA has cited a different figure from its own vantage point. In a communication dated August 27, 2026, the agency said it was aware of at least 30 patients who experienced adverse events after intravenous glutathione. The two counts come from different agencies and different dates and should be read as such, not added together. Reported symptoms across the agencies' descriptions include fever, chills, pain, dizziness, and signs of shock or sepsis-like reactions, patterns consistent with excessive endotoxin exposure.

Why dietary supplement grade glutathione is the problem

The FDA's position is that ingredients labeled for dietary supplement use should not be used to compound sterile injectable drugs. Such ingredients may contain impurities and contaminants, including endotoxins, that can be harmful when administered by injection. Endotoxins are fragments of certain bacteria. They can provoke a strong inflammatory response when they enter the bloodstream even when no live organism is present, which is why an injectable can cause fever, low blood pressure, and sepsis-like symptoms without an active infection.

Injection bypasses the skin and other barriers that normally guard against microorganisms and toxins, so a sterility failure, a contaminated ingredient, or particulate matter carries more direct risk than the same substance taken by mouth. That is the core reason regulators treat the source and grade of an injectable ingredient as a safety-critical detail.

The Medisca ingredient link named by the FDA

In its August 27, 2026 communication, the FDA identified glutathione from Medisca Inc., with U.S. headquarters in Plattsburgh, New York, and pointed to Lot #229536 as a common source of glutathione obtained by multiple compounding pharmacies. The FDA said two pharmacies in Texas had conducted recalls related to elevated endotoxin, and it urged compounders that received dietary supplement grade glutathione from Medisca to contact their customers and instruct them to stop using the affected product.

The CDC's own summary does not name an ingredient supplier or lot number. The Medisca and Lot #229536 details are attributed here to the FDA. A shared supplier does not by itself prove the cause of every reported illness, and the investigation into how many pharmacies, lots, and patients are ultimately involved is still open.

How this connects to the 2026 compounding recalls

The federal investigation sits on top of a run of individual recalls earlier in 2026. Several Texas compounding pharmacies pulled injectable glutathione over elevated endotoxin, including a nationwide recall by Centric Compounding of Houston that the FDA posted in September and two earlier Texas recalls. See our coverage of the Centric Compounding recall for the affected products and lot numbers. The new element in September is the CDC-coordinated multistate investigation that ties these threads to a common ingredient problem rather than to a single pharmacy.

Why this reaches telehealth and IV-drip patients

Injectable glutathione, along with combination drips such as Myer's cocktail and immune-support blends, is frequently marketed through telehealth wellness, longevity, and IV-therapy providers, prescribed remotely and shipped to patients or administered in clinics. That distribution model means an affected patient may not have a local pharmacist to consult and may be several steps removed from the pharmacy that compounded the product. When a recall or safety warning depends on the pharmacy reaching each recipient, the mail-order and clinic-based nature of these products makes follow-through harder.

What patients and clinicians can do

This is general information, not medical advice. Decisions about any specific product or symptom should be made with a licensed clinician. The CDC's published guidance for this situation includes the following.

• Before receiving injectable glutathione, ask the provider whether the product was made with ingredients intended for injection, and ask about any recalls or safety warnings.
• Clinicians should not administer injectable glutathione products compounded using dietary supplement grade ingredients.
• Compounders should stop using dietary supplement labeled glutathione for injectables and contact customers who received affected products.
• Report symptoms such as fever, chills, nausea, or injection-site reactions to a healthcare provider, and report adverse events to the FDA's MedWatch program at 1-800-332-1088.

What remains unsettled

The investigation is ongoing, so figures are provisional. The CDC count (more than 25 ill in at least four states as of September 15, 2026) and the FDA count (at least 30 patients as of August 27, 2026) reflect different agency views at different times. The CDC has not publicly named an ingredient supplier, and no deaths have been reported. Whether additional lots, pharmacies, or states are drawn in, and how firmly each illness is linked to a specific product, are questions the agencies have not yet resolved on the record.